Gemma Azaceta

Zaragoza, AR, Spain

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications

NK92 cells stably transfected with CD16 are efficient against multiple myeloma cells ex vivo and in vivo, especially if combined with daratumumab.

NK92 cells stably transfected with CD16 are efficient against multiple myeloma cells ex vivo and in vivo, especially if combined with daratumumab.

Journal: Oncoimmunology
Published: September 25, 2025

The Combination of Ibrutinib with BH3 Mimetics or Dichloroacetate Is Effective in B-CLL.

The Combination of Ibrutinib with BH3 Mimetics or Dichloroacetate Is Effective in B-CLL.

Journal: Cells
Published: July 16, 2025

Real world outcomes of momelotinib in myelofibrosis patients with anemia: results from the MOMGEMFIN study.

Real world outcomes of momelotinib in myelofibrosis patients with anemia: results from the MOMGEMFIN study.

Journal: Blood cancer journal
Published: December 15, 2024

Genetic evolution and relapse-associated mutations in adult T-cell acute lymphoblastic leukemia patients treated in PETHEMA trials.

Genetic evolution and relapse-associated mutations in adult T-cell acute lymphoblastic leukemia patients treated in PETHEMA trials.

Journal: HemaSphere
Published: September 20, 2024

AML typical mutations (CEBPA, FLT3, NPM1) identify a high-risk chronic myelomonocytic leukemia independent of CPSS molecular.

AML typical mutations (CEBPA, FLT3, NPM1) identify a high-risk chronic myelomonocytic leukemia independent of CPSS molecular.

Journal: Blood advances
Published: May 14, 2024

Granulomatous dermatitis in the context of chronic myelomonocytic leukemia: More than just reactive infiltrates. An illustrative case report with literature review.

Granulomatous dermatitis in the context of chronic myelomonocytic leukemia: More than just reactive infiltrates. An illustrative case report with literature review.

Journal: Journal of cutaneous pathology
Published: June 24, 2023

Dinaciclib synergizes with BH3 mimetics targeting BCL-2 and BCL-XL in multiple myeloma cell lines partially dependent on MCL-1 and in plasma cells from patients.

Dinaciclib synergizes with BH3 mimetics targeting BCL-2 and BCL-XL in multiple myeloma cell lines partially dependent on MCL-1 and in plasma cells from patients.

Journal: Molecular oncology
Published: May 08, 2023

Ecto-calreticulin expression in multiple myeloma correlates with a failed anti-tumoral immune response and bad prognosis.

Ecto-calreticulin expression in multiple myeloma correlates with a failed anti-tumoral immune response and bad prognosis.

Journal: Oncoimmunology
Published: November 07, 2022

Granulomatous Dermatitis Heralding Myelodisplastic/Myeloproliferative Neoplasms. Neoplastic or Reactive Cells? A Study of 2 Cases.

Granulomatous Dermatitis Heralding Myelodisplastic/Myeloproliferative Neoplasms. Neoplastic or Reactive Cells? A Study of 2 Cases.

Journal: The American Journal of dermatopathology
Published: February 16, 2022

Harnessing the Potential of NK Cell-Based Immunotherapies against Multiple Myeloma.

Harnessing the Potential of NK Cell-Based Immunotherapies against Multiple Myeloma.

Journal: Cells
Published: December 21, 2021

Expanded NK cells from umbilical cord blood and adult peripheral blood combined with daratumumab are effective against tumor cells from multiple myeloma patients.

Expanded NK cells from umbilical cord blood and adult peripheral blood combined with daratumumab are effective against tumor cells from multiple myeloma patients.

Journal: Oncoimmunology
Published: January 18, 2021

Expanded and activated allogeneic NK cells are cytotoxic against B-chronic lymphocytic leukemia (B-CLL) cells with sporadic cases of resistance.

Expanded and activated allogeneic NK cells are cytotoxic against B-chronic lymphocytic leukemia (B-CLL) cells with sporadic cases of resistance.

Journal: Scientific reports
Published: July 24, 2020
Showing 1-12 of 21

Last Updated: 09/26/2026